Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults

Vaccine

Volumn 29, Issue 45, 2011, Pages 7920-7924

  Leeb, Alan ^a   Carcione, Dale ^b   Richmond, Peter C ^c,d   Jacoby, Peter ^d   Effler, Paul V ^b  

^a Illawarra Medical Centre   (Australia)

^b DEPARTMENT OF HEALTH   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

2010; Adults; Adverse events; Influenza; Safety; Trivalent inactivated; Vaccine

Indexed keywords

ANTIPYRETIC ANALGESIC AGENT; INFLUENZA VACCINE;

ADULT; AGED; ARTHRALGIA; ARTICLE; AUSTRALIA; CONVULSION; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; FATIGUE; FEBRILE CONVULSION; FEMALE; FEVER; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYALGIA; PAIN; PATIENT ASSESSMENT; PRIORITY JOURNAL; RIGOR; SEASONAL INFLUENZA; SELF REPORT; SWELLING; VOMITING;

ADULT; AGED; AUSTRALIA; DRUG TOXICITY; EDEMA; FEMALE; FEVER; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PAIN; RETROSPECTIVE STUDIES; VACCINES, INACTIVATED;

EID: 80053621500     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.073     Document Type: Article

References (27)

1. Jim Bishop. Letter from the Chief Medical Officer, 30 July 2010. Available from [cited 5 January 2011]. http://www.healthemergency.gov.au/internet/healthemergency/publishing.nsf/content/012B6C32F2D2B4A1CA25763C001A6F73/$File/CMO-letter-30July2010.pdf.
2. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2010 southern hemisphere influenza season. WHO; Revised 8 Oct 2009. Available from [cited 25 July 2011]. http://www.who.int/csr/disease/influenza/200909_Recommendation.pdf.
3. Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, Geelhoed GC, Mascaro F, Scully M, Weeramanthri TS. Severe febrile reactions to a 2010 trivalent inactivated influenza vaccine in young children in Western Australia. BMJ Open 2011. Available from [cited 25 July 2011]. http://bmjopen.bmj.com/content/early/2011/05/28/bmjopen-2010-000016.full.pdf.
4. Therapeutic Goods Administration. Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination: status report as at 2 July 2010. Updated 24 September 2010. Available from [cited 22 July 2011]. http://www.tga.gov.au/pdf/alerts-medicine-seasonal-flu-100702.pdf.
5. The Australian Immunisation Handbook, 9th ed. Available from [cited 25 July 2011]. http://www.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-home.
6. Greenberg M, Van Dinther K, Maraskovsky E. Adverse Events In Children Associated with 2010 Southern Hemisphere Seasonal Influenza Vaccine. 45th National Immunization Conference. March 28-31, 2011. Washington, DC. Abstract 25435. Available from [cited 25 July 2011]. http://cdc.confex.com/cdc/nic2011/webprogram/Paper25435.html.
7. Therapeutic Goods Administration. Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children, dated 8 October 2010. Available from [cited 25 July 2011]. http://www.tga.gov.au/alerts/medicines/vaccine-overview.htm.
8. Blyth C.C., Currie A.J., Wiertsema S.P., Conway N., Kirkham L.A., Fuery A., Mascaro F., Geelhoed G.C., Richmond P.C. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. Vaccine 2011, 29(July (32)):5107-5113.
9. Fluvax® vaccine 2010 (AUST R 91583) Product Information, May 2010, CSL Biotherapies, Victoria, Australia. Available from [cited 25 July 2011]. http://fluvax.healthwatch.com.au/site/Fluvax2010.pdf.
10. Salisbury DM. Risk of febrile convulsions in children aged under five years and seasonal influenza vaccines marketed by Pfizer Vaccines (Enzira® and CSL Biotherapies generic influenza vaccine) Dear colleague letter dated 28 July 2010. Available from [cited 25 July 2011]. http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_117984.
11. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Use of CSL Seasonal Influenza Vaccine (Afluria) in the United States During 2010-11. Morbidity and Mortality Weekly Report (MMWR) August 13, 2010/59(31);989-992. Available from [cited 25 July 2011]. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5931a4.htm.
12. Food and Drug Administration. Biologics License Application for Afluria manufactured by CSL, Limited. Number: 125254, September 19, 2007. Available from [cited 25 July 2011]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm127190.pdf.
13. CSL AFLURIA®, Influenza Virus Vaccine, 2010-2011 Formula Influenza Virus Vaccine STN BL 125254/181. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm220730.pdf.
14. Spila-Alegiani S., Salmaso S., Roat M.S., Tozzi A.E., Raschetti R. and the Italian SVEVA group. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Vaccine 1999, 17:1898-1904.
15. Summary of Adverse Event Following Immunisation Reports, Department of Health, Western Australia, 2010. Available from [cited 25 July 2011]. http://www.public.health.wa.gov.au/cproot/3684/2/Dale%20-%20Western%20Australia%20Adverse%20Events%20Following%20Immunisation%20Report_final_20110228_PA%20-%2016%20March%202011.pdf.
16. Potter C.W., Jennings R., McLaren C., Edey D., Stuart-Harris C.H., Brady M. A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group. J Hyg (Lond) 1975, 75(December (3)):353-362.
17. Gross P.A., Ennis F.A., Gaerlan P.F., Denson L.J., Denning C.R., Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977, 136(November (5)):623-632.
18. Wise TG, Dolin R, Mazur MH, Top FH Jr, Edelman R, Ennis FA. Serologic responses and systemic reactions in adults after vaccination with bivalent A/Victoria/75-A/New Jersey/76 and monovalent B/Hong Kong/72 influenza vaccines. J Infect Dis. 1977 Dec;136 Suppl:S507-17.
19. al-Mazrou A., Scheifele D.W., Soong T., Bjornson G. Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. CMAJ 1991, 145(August (3)):213-218.
20. Scheifele D.W., Bjornson G., Johnston J. Evaluation of adverse events after influenza vaccination in hospital personnel. CMAJ 1990, 142(January (2)):127-130.
21. Warburton M.F., Duxbury AE Deoxycholate-split influenza vaccines in infants and young children. International Symposium on Influenza Vaccines for Men and Horses, London 1972; Symp. Series Immunobiol. Standard, vol. 20 1973, 92-98.
22. Letter to CSL Biotherapies from Mary Malarkey, Director, Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research, Food and Drug Administration dated June 15, 2011. Available from [cited 25 July 2011]. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm259888.htm.
23. World Health Organization. Weekly Epidemiological Record. 24 January 2003 No. 4, 2003, 78, 17-24. Available from [cited 25 July 2011]. http://www.who.int/wer/2003/en/wer7804.pdf.
24. Skowronski D.M., Strauss B., De Serres G., MacDonald D., Marion S.A., Naus M., Patrick D.M., Kendall P. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event?. Clin Infect Dis 2003, 36(March (6)):705-713.
25. Influvac®-PI-AUST-1Dec 2009 M Solvay Pharmaceuticals, NSW, Australia. Available from [cited 25 July 2011]. http://calastica.com/pdf/fluvax/2010/influvac.PI.pdf.
26. Australian Government, National Health and Medical Research Council, c2004, General guidelines for medical practitioners on providing information to patients. Available from [cited 25 July 2011]. http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/e57.pdf.
27. CSL Afluria Influenza Virus Vaccine Package Insert. STN BL 125254/181. Table 5: Proportion of Subjects with Solicited Fever within 7 days of Vaccination with AFLURIA or U.S. Licensed Comparator Vaccine. Available from [cited 25 July 2011]. http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm220730.pdf.